retatrutide mechanism triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology First Retatrutide phase 3 data,

Minder EI, Schneider-Yin X

Nevertheless, the pooled analysis of 16 trials suggested improvements in the summary measure of patients' global functioning (assessed with the Clinical Global Impressions [CGI-I] scale) after 12 and 24 weeks of (but not after 52 weeks) of ALCAR treatment (1-3 g/day) and in cognitive performance (assessed with the Mini-Mental State Examination [MMSE] scale) after 24 weeks (but not at 12 or 52 weeks) (104)

It is less clear why the FDA is requiring a specific cardiovascular study on higher-than-normal levels of exenatide, Bydureons active ingredient we were quite surprised and disappointed by this news, which seems difficult to justify given other drugs on the market with similar questions that have been approved

10.1152/ajpendo.00565.2005 113

15 It is not our intention to advocate the use of AOM, in particular GLP-1 RA, for every patient with obesity

PPIs should be used under physician guidance rather than indefinitely without review, as long-term PPI use affects magnesium and B12 absorption